Men with HF have worse long-term survival rates if they also have severe depression, bipolar disorder, or schizophrenia, according to a study published in Circulation: Heart Failure. Researchers assessed more than 20,000 people with HF from 2002- 2017. During a median follow-up of 7 years, men with severe depression, bipolar disorder, or schizophrenia were 36% more likely to die from any cause than those without these conditions. Rates of 10-year mortality risk were 54.8% in men without a mental health disorder and 64.3% in men with such a disorder.

SGLT2 Inhibitors May Reduce HF Hospitalization Risk

For patients with type 2 diabetes (T2D) with or without CVD, use of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) correlated with a reduced risk for HF hospitalization, according to a study published in Annals of Internal Medicine. Investigators conducted a population-based cohort study of adults with T2D with and without CVD (52,901 and 133,139 matched pairs, respectively) to examine whether SGLT2 inhibitors and GLP-1 RAs are associated with differential cardiovascular benefit. For patients with CVD, the initiation of SGLT2 inhibitor therapy vs GLP-1 RA therapy was associated with a slightly lower risk for myocardial infarction or stroke (HR, 0.90). Among patients without CVD, the risk was similar (HR, 1.07). Reductions in HF hospitalization risk were seen with initiation of SGLT2 inhibitor therapy vs GLP-1 RA therapy, regardless of baseline CVD, in patients with CVD (HR, 0.71) and those without CVD (HR, 0.69).